5 Aug 2019 11:00
5 August 2019
Notification of full year results date
Clinigen Group plc ('Clinigen' or the 'Group', AIM: CLIN), the global pharmaceutical and services company, will announce its full year results for the year ended 30 June 2019 on Thursday 19 September 2019.
A group analyst briefing will be held at 9:30am on Thursday 19 September 2019 at Instinctif Partners' offices at 65 Gresham Street, London EC2V 7NQ.
Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email clinigen@instinctif.com to register.
-Ends-
For further information, please contact:
Clinigen Group plc | Tel: +44 (0) 1283 495 010 |
Shaun Chilton, Group Chief Executive Officer |
|
Nick Keher, Group Chief Financial Officer |
|
Matt Parrish, Head of Investor Relations |
|
|
|
Numis Securities Limited - Nominated Adviser & Joint Broker | Tel: +44 (0) 20 7260 1000 |
James Black / Freddie Barnfield / Freddie Naylor-Leyland |
|
|
|
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas |
|
|
|
Instinctif Partners (media relations) | Tel: +44 (0) 20 7457 2020 |
Adrian Duffield / Melanie Toyne-Sewell / Rozi Morris | Email: clinigen@instinctif.com |
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific. In October 2018, the Group acquired CSM, a specialist provider of packaging, labelling, warehousing and distribution services, with sites in the US and Europe, and iQone, a specialist pharmaceutical company in Switzerland.
For more information, please visit www.clinigengroup.com